Company intelligence / Profile preview

PranaX

Ownership: Private
Development stage: Phase 1

Overview

PranaX focuses on developing exosome-based products to boost the immune system and promote long-term health. Its subsidiary Rejenevie Therapeutics has shown promising results in preclinical and Phase 1 clinical trials for immune restoration.

Therapeutic areas: OtherInfectious Diseases
Modalities: Exosomes
Industry: Biotech

Drug pipeline

1 asset

ExoWELL

Preclinical

Partnerships

Exclusive license from MD Anderson for stem cell exosome products

Beyond the preview

Go deeper on PranaX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PranaX.